CHOICE Trial: Same mortality, less aortic regurgitation and need for a second prosthetic for Edwards Sapien XT valve versus Medtronic CoreValve

So far, there had been no published randomized studies comparing balloon-expandable Edwards’s prosthesis and self-expandingCoreValve. The aim of this study was to compare the results between the two thin aortic prosthesis in high-risk surgical patients with severe symptomatic aortic stenosis undergoing valve replacement by percutaneous transfemoral access. This was a multicenter work (five centers in Germany) not sponsored by industry which randomized 121 patients to receive Edwards Sapien XT and 120 patients receiving CoreValve.

The primary endpoint was the device success defined by VARC (Valve AcademicResearchConsortium) criteriapost procedure.The success of the device was 95.9 % for the balloon-expandable valve versus 77.5% for the self-expanding valve (p < 0.001) and this difference was based on the significantly lower frequency of moderate / severe aortic regurgitation (4.1 % versus 18.3 %, P < 0.01) and less need for a second prosthesis (0.8 % versus 5.8 %, P = 0.03).Cardiovascular mortality at 30 days was 4.1 % for Edwards and 4.3 % for CoreValve (p = 0.99). Bleeding and vascular complications were also similar.The need for permanent pacemaker was also lower for balloon expandable valve (17.3 % versus 37.6 %, P = 0.001).

Conclusion

In patients with severe aortic stenosis at high surgical risk undergoing percutaneous valve replacement, balloon expandable prosthesis showed a higher success rate of the device.

Article

Editorial

2_mohamed_abdel_wahab_slides
Mohamed Abdel-Wahab
2014-03-31

Original title: A Randomized Comparison of Self-Expandable and Balloon-Expandable Prostheses in Patients Undergoing TransfemoralTranscatheter Aortic Valve Replacement – The CHOICE Trial.

More articles by this author

CORP-2 Trial: Colchicine effective in reducing the recurrence of pericarditis associated withconventional anti-inflammatory pattern.

Colchicine is effective in treating an acute pericarditis event and initial recurrences;however, there is no conclusive data on its efficacy and safety in the...

Melody

The ducts of the right ventricle to the pulmonary artery are used in approximately 20 % of all patients with congenital defects including tetralogy...

Negative ultrasensitive troponin T values may help discriminate patients with chest pain in the emergency

New laboratory tests can detect minimally elevated  levels few hours before regarding detection methodologies of previous generations.The hypothesis of this study is that patients...

LAPLACE 2: Evolocumab effective in reducing LDL associated with statins

There are several patients who do not reach recommended LDL cholesterol despite maximally tolerated doses of statins levels.The Evolocumab is a monoclonal antibody that...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...